49
Participants
Start Date
September 27, 2019
Primary Completion Date
July 4, 2022
Study Completion Date
May 30, 2025
Avelumab
Patients with newly diagnosed cHL will receive 4 doses of single agent avelumab 10 mg/kg intravenously given every 2 weeks.
Austin Health, Heidelberg
Heartlands Hospital, Birmingham
Beatson Hospital, Glasgow
Leicester Royal Infirmary, Leicester
St George's Hospital, London
Christie Hospital, Manchester
Norfolk and Norwich University Hospital, Norwich
Churchill Hospital, Oxford
Derriford Hospital, Plymouth
Royal Stoke University Hospital, Stoke
The Royal Marsden Hospital, Sutton, Sutton
Collaborators (1)
Pfizer
INDUSTRY
University College, London
OTHER